Jamie Rhode shares how Screendoor achieves consistency in an unpredictable industry. By combining data-driven analysis with experience from her days at Bloomberg and Verdis, she explains how to balance exposure across 20+ fund managers—without losing focus or agility. #Leadership #VentureCapital #Investing #Entrepreneurship #PortfolioDesign #JamieRhode #InnovationAndLeadership
Jamie Rhode breaks down one of venture capital’s most misunderstood topics: the difference between alpha and beta. She explains how the “beta of venture” — the market’s average 3X net return over 40 years — is already impressive, but the real magic happens when investors find alpha, or the performance…
Julie Wainwright explains the deeper psychology of luxury branding. Luxury is more than function—it’s romance, aspiration, and identity. Brands invest heavily in image, weaving a story that makes their products desirable. But as Julie points out, the products themselves must also deliver: exceptional quality, timeless design, and in many cases,…
Julie Wainwright shares the scrappy early days of building The RealReal. At launch, supply was the biggest challenge—home parties and friends-of-friends were not scalable. Julie tried a stylist program in Los Angeles, pitching directly to agencies and stylists, but early results were underwhelming. Then came a turning point: a celebrity…
Julie Wainwright shares powerful insights for founders trying to break through the “hundreds of millions” ceiling. She explains why understanding your total available market is the foundation—if the market is truly massive, your current revenue may only scratch the surface. But identifying your true lever—supply, demand, or technology—becomes the key…
Julie Wainwright walks us through the story of The RealReal — the first company to bring authenticated luxury resale online at scale. From fine jewelry to handbags to watches, she explains how the platform created a new category by taking full possession of items, guaranteeing authentication, and serving millions of…
What if homes could be designed not just with technology—but around the emotions and experiences that matter most to families? Glenn Gow explains how AI can capture the details that make each house feel special, from favorite music and room layouts to pool temperatures and scents. With AI, the next…
Glenn Gow, known as The CEO Success Coach, explains how he pushes leaders to embrace AI in ways that go beyond the hype. For him, it’s about three critical layers: adopting AI in daily operations, maximizing it in software development, and embedding it into core offerings. CEOs who hesitate risk…
Glenn Gow shares what happens when CEOs plateau at hundreds of millions and want to push past the billion-dollar mark. His first step isn’t about strategy or scale—it’s about asking the question why. Without clarity on deeper motivations, any plan for growth risks being hollow.
Glenn Gow shares his remarkable journey from running a Silicon Valley consulting firm that served Apple, Google, Meta, and Microsoft, to becoming a venture capitalist and ultimately a CEO coach. His transition was fueled by a passion for helping leaders grow and by recognizing the power of adding value in…
Serina Therapeutics is preparing to launch a critical early-stage clinical trial for their apomorphine-based therapy. By late Q1 or early Q2 next year, they expect to know if they’ve eliminated the painful skin reactions that have plagued existing therapies—a massive milestone for both patients and the biotech community. #InnovationAndLeadership #ParkinsonsResearch…
Current therapies for Parkinson’s patients facing motor fluctuations are far from ideal—infusion pumps that irritate the skin and limit quality of life. Serina Therapeutics is taking a bold step forward by reimagining apomorphine delivery through its unique polymer platform. The result? A shot at delivering consistent, long-lasting relief with fewer…
Multiple Shots on Goal in Biotech #shorts Biotech is often described as a “binary bet”—one product, one chance, and if the trial data doesn’t hold, it all collapses. But Serina Therapeutics is rewriting that narrative. With a platform spanning multiple therapeutic areas, they are building not just one pipeline, but…
What if one medical breakthrough could transform millions of lives—and create companies valued in the trillions? Steve Ledger and Simba Gill reveal why Serina Therapeutics is positioned to make late-stage Parkinson’s and other devastating diseases more treatable, potentially reshaping healthcare and financial markets alike. #InnovationAndLeadership #Biotech #HealthcareInnovation #ParkinsonsResearch #SerinaTherapeutics #FlagshipPioneering…
Blair LaCorte unpacks the uncomfortable truth that sometimes “working harder” just means doubling down on a bad strategy. At one of the world’s biggest investment firms, he faced the reality that a venture fund wasn’t delivering returns, and keeping it alive would only waste time and credibility. Making the call…
At one of the world’s top private equity firms, Blair LaCorte saw firsthand how easy it was to fall prey to confirmation bias. TPG was winning big, but that success risked blinding them to what wasn’t working. When their venture bets stalled, Blair and the team realized something crucial—venture wasn’t…
In the late 1990s, Microsoft made its largest private equity investment outside of telecom—a $400 million bet on VerticalNet. Blair La Corte shares the behind-the-scenes story of how alignment, timing, and even a bit of fear shaped one of the biggest moves of the dot-com era. It wasn’t just about…
Blair La Corte reflects on the meteoric rise of Internet Capital Group, a venture capital firm that bet exclusively on internet companies during the dot-com boom. Starting with just $3 million in revenue, the firm went public at $14 a share—only to skyrocket to a $10 billion valuation as the…
Michael Episcope shares how investor behavior has evolved—and why net worth often matters more than age. A decade ago, Baby Boomers preferred face-to-face relationships while Gen X leaned digital. Today, even older generations use the internet to discover new opportunities. What truly differentiates investors, Michael argues, is wealth level, not…
Michael Episcope breaks down why ultra-high-net-worth individuals lean so heavily on real estate. Unlike volatile liquid assets, real estate provides something tangible—cash flow you can see, touch, and feel. It’s tax-efficient, historically as strong as the stock market, and it rewards patience. Those who buy and hold quality properties often…
Michael Episcope recalls the early years of Origin Investments and how persistence shaped their breakthrough. After repeating the same strategy without results, they realized they had to pivot or risk stagnation. Hiring their first marketing lead and investor relations specialist became a turning point, proving that growth wasn’t about a…
Michael Episcope shares how Origin Investments broke out by choosing focus over pedigree. Instead of chasing pension funds in 2015, they doubled down on serving high-net-worth investors—and paired a great product with real marketing. The result: 8 years to 80 investors… then 2 years to 500, and ~4,500 today. The…
Philanthropy isn’t just about writing checks—it’s about shaping values across generations. Hillel Presser explains how R360’s Giving Circle is inspiring entrepreneurial families to treat giving back as their “next mountain to climb.” It’s not just members donating; it’s about intentionally involving their children in discussions on values, community, and responsibility.…
Recognition doesn’t just happen—it’s earned through consistent effort and credibility. Hillel Presser shares why many highly skilled professionals struggle: they’ve mastered their craft but haven’t yet mastered visibility. To become the name on everyone’s lips, you have to combine work ethic with intentional positioning. It starts with relentless dedication. You…
